Tryp Therapeutics Inc.

Recent News

  • Tryp Therapeutics stellt IND-Antrag auf klinische Studie der Phase 2a zu Essstörungen

    San Diego, California--(Newsfile Corp. - Mittwoch, 22. September 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp"), ein Pharmaunternehmen mit Fokus auf der Entwicklung von Psilocybin-basierten Verbindungen für Krankheiten mit ungedecktem medizinischem Bedarf, gab heute seine Einreichung eines Investigational New Drug (" IND ")-Antrags bei der US-amerikanischen Food and Drug Administration (FDA) bekannt. Dabei soll sein klinischer Kandidat TRP-8802 in einer Studie der Phase 2a zur Behandlung von Patient*innen mit Essstörungen evaluiert werden.Die Studie wird in Zusammenarbeit mit Dr. Jennifer...

    2021-09-22 2:30 PM EDT
  • Tryp Therapeutics Submits IND Application for Phase 2a Clinical Trial in Eating Disorders

    San Diego, California--(Newsfile Corp. - September 22, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today that it has submitted an Investigational New Drug ("IND") application to the U.S. Food and Drug Administration ("FDA") to evaluate its clinical candidate, TRP-8802, in a Phase 2a study for the treatment of patients with eating disorders.The trial is being conducted with Jennifer Miller, M.D., from the...

    2021-09-22 7:05 AM EDT
  • Tryp Therapeutics to Present at Oppenheimer Fall Healthcare Summit

    San Diego, California--(Newsfile Corp. - September 16, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today that it will present virtually at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit.The conference will be held virtually on September 20-23, 2021. Greg McKee, Chairman and CEO of Tryp, will provide an overview of the business and its pipeline including Tryp's Psilocybin-For-Neuropsychiatric Disorders (PFNTM) program for...

    2021-09-16 7:05 AM EDT
  • CORRECTION FROM SOURCE: Tryp Therapeutics to Present at H.C. Wainwright Global Investment Conference

    A correction from Tryp Therapeutics Inc. is being issued for the news release disseminated earlier today. The correction relates to an error in the presentation date and the disclosure of stock option grants. The presentation will be available on-demand beginning September 13, 2021 at 7:00 a.m. EDT. No other material changes were required in the body of the release.San Diego, California--(Newsfile Corp. - September 1, 2021) -  Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp"), a pharmaceutical company focused on developing...

    2021-09-01 10:01 AM EDT
  • Tryp Therapeutics to Present at H.C. Wainwright Annual Global Investment Conference

    San Diego, California--(Newsfile Corp. - September 1, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, announced today that it will present at the H.C. Wainwright Annual Global Investment Conference.The conference will be held virtually on September 13-15, 2021. Greg McKee, Chairman and CEO of Tryp, will provide an overview of the business and its pipeline including Tryp's Psilocybin-For-Neuropsychiatric Disorders (PFNTM) program...

    2021-09-01 7:05 AM EDT
  • Tryp Therapeutics Completes Psychotherapy Training for Phase 2a Study at the University of Florida

    San Diego, California--(Newsfile Corp. - August 24, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today it has completed the training of psychotherapists for its upcoming Phase 2a clinical trial using synthetic psilocybin in combination with psychotherapy for overeating disorders. The training was conducted by Fluence, which is led by researchers and psychotherapists with direct experience in psychedelic clinical trials...

    2021-08-24 7:05 AM EDT
  • Tryp Therapeutics Appoints Dennis Langer, M.D., J.D. as Senior Advisor

    San Diego, California--(Newsfile Corp. - August 18, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today the appointment of Dennis Langer, M.D., J.D., as Senior Advisor to the Company.Dr. Langer has been a Director, Co-Founder, and CEO of various public and private biotechnology, specialty pharmaceutical, and diagnostic companies. He previously served as Senior Vice President of Research and Development at...

    2021-08-18 7:05 AM EDT
  • Tryp Therapeutics Partners with Calvert Labs to Conduct Exploratory Studies for Proprietary Psilocybin Formulations

    San Diego, California--(Newsfile Corp. - August 10, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, announced today an agreement with Calvert Labs to design and execute exploratory studies related to Tryp's Psilocybin-for-Neuropsychiatric Disorders (PFNTM) program.Calvert Labs, an Altasciences company, has a proven track record of executing FDA-approved studies across a broad range of the

    2021-08-10 7:05 AM EDT